| Literature DB >> 25063185 |
Nandini Rao, Fengyu Song, Deepali Jhamb, Mu Wang, Derek J Milner, Nathaniel M Price, Teri L Belecky-Adams, Mathew J Palakal, Jo Ann Cameron, Bingbing Li, Xiaoping Chen, David L Stocum1.
Abstract
BACKGROUND: To gain insight into what differences might restrict the capacity for limb regeneration in Xenopus froglets, we used High Performance Liquid Chromatography (HPLC)/double mass spectrometry to characterize protein expression during fibroblastema formation in the amputated froglet hindlimb, and compared the results to those obtained previously for blastema formation in the axolotl limb.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25063185 PMCID: PMC4222900 DOI: 10.1186/1471-213X-14-32
Source DB: PubMed Journal: BMC Dev Biol ISSN: 1471-213X Impact factor: 1.978
Figure 1Histological section of regenerating froglet hindlimb at 12 days post-amputation through the mid tibia-fibula. The section is cut through the dorsoventral plane such that the tibia (T) and the accompanying flexor and extensor muscle masses are visible (red). A cartilage collar (CC) has formed around the tibia for some distance proximal to the amputation plane that merges distally with a similar collar surrounding the fibula. A fibroblastema (FB) that will form the cartilage spike is present between the merge point of the cartilage collars and the apical epidermal cap (arrow). Yellow line indicates the plane of tissue harvest.
Figure 2Pie chart showing the percentage distribution of the 820 proteins among different biological categories and sub-categories.
Patterns of up or down regulation observed at all four post-amputation time points or three of the four time points
| u | u | u | u | d | d | d | d |
| d/n | u | u | u | u/n | d | d | d |
| u | u | u | d/n | d | d | d | u/n |
| u | d/n | u | u | d | u/n | d | d |
| u | u | d/n | u | d | d | u/n | d |
u = up regulation, d = down regulation, n = no change. Slash means “or”; dpa = days post-amputation.
Number of Xenopus proteins in each biological process category that are up regulated (U) or down regulated (D) on all dpa or 3 of 4 dpa, and U/D ratios
| Signaling | 93 | 49 (52.7) | 31 (33.3) | 1.6 |
| Transport | 67 | 30 (46.6) | 32 (50.0) | 0.9 |
| VT | 44 | 20 (45.5) | 24 (54.5) | 0.8 |
| NVT | 23 | 10 (43.5) | 8 (34.8) | 1.3 |
| Transcription | 104 | 51 (49.0) | 36 (34.6) | 1.4 |
| Chromatin associated | 24 | 13 (54.2) | 7 (29.2) | 1.9 |
| Transcription factors | 41 | 19 (46.3) | 16 (39.0) | 1.2 |
| RNA processing | 39 | 19 (48.7) | 13 (33.3) | 1.5 |
| Translation | 78 | 48 (62.8) | 15 (20.6) | 3.1 |
| Ribosomal proteins | 55 | 34 (61.8) | 10 (18.2) | 3.4 |
| Translation factors | 23 | 15 (60.9) | 5 (21.7) | 3.0 |
| Cytoskeleton | 104 | 40 (38.5) | 41 (39.4) | 0.9 |
| Muscle | 28 | 3 (10.7) | 23 (82.1) | 0.1 |
| Non-Muscle | 76 | 37 (53.0) | 18 (21.0) | 2.1 |
| Extracellular matrix | 41 | 25 (61.0) | 4 (9.8) | 6.3 |
| Metabolism | 135 | 39 (37.1) | 68 (50.3) | 0.7 |
| Carbohydrate | 72 | 16 (22.2) | 39 (54.2 | 0.4 |
| Non-Carbohydrate | 63 | 23 (36.5) | 29 (44.4) | 0.8 |
| Cell Protection | 80 | 39 (48.70) | 21 (26.3) | 1.9 |
| Inflamm-Related | 38 | 16 (42.1) | 11 (28.9) | 1.5 |
| Apoptosis-Related | 10 | 5 (50.0) | 5 (50.0) | 1.0 |
| Chaperones | 32 | 18 (56.3) | 5 (15.6) | 3.6 |
| Degradation | 64 | 27 (42.2) | 21 (32.8) | 1.3 |
| Ubiquit/Proteasome | 29 | 11 (37.9) | 10 (34.4) | 1.1 |
| Other | 35 | 16 (45.7) | 11 (31.4) | 1.5 |
| Cell cycle | 54 | 21 (38.9) | 18 (33.3) | 1.2 |
| G1/S | 15 | 6 (40.0) | 7 (46.7) | 0.9 |
| M | 18 | 8 (44.4) | 6 (33.4) | 1.3 |
| Other | 21 | 7 (33.3) | 5 (23.8) | 1.4 |
| Total | 369 | 287 | 1.3 | |
Numbers in parentheses indicate percentages of the total proteins up or down regulated. VT = vesicle-associated transport and NVT non-vesicle-associated transport.
Number of Xenopus proteins up regulated (U) or down regulated (D) with FC =/>2 at one or more time points after amputation, and the ratio of U/D, according to biological process category
| Signaling | 30 | 13 | 2.3 |
| Transport | 11 | 19 | 0.6 |
| Transcription | 24 | 21 | 1.1 |
| Translation | 6 | 2 | 3.0 |
| Cytoskeleton | 27 | 20 | 1.4 |
| Muscle | 1 | 13 | 0.1 |
| Non-Muscle | 26 | 7 | 3.7 |
| Extracellular matrix | 8 | 2 | 4.0 |
| Metabolism | 10 | 12 | 0.8 |
| Carbohydrate | 2 | 6 | 0.3 |
| Non-Carbohydrate | 8 | 6 | 1.3 |
| Cell protection | 11 | 9 | 1.2 |
| Degradation | 7 | 5 | 1.4 |
| Cell cycle | 12 | 9 | 1.3 |
| G1/S | 3 | 4 | 0.8 |
| M | 5 | 4 | 1.3 |
| Other | 4 | 1 | 4.0 |
Percentage of up or down regulated Xenopus proteins with FC =/>2 at one time point (TP), 2 time points or 3–4 time points after amputation, according to biological process category
| Signaling | 53.6 | 14.3 | 32.1 |
| Transport | 42.4 | 19.0 | 38.1 |
| Transcription | 48.8 | 20.9 | 30.2 |
| Translation | 66.6 | 33.3 | 00.0 |
| Cytoskeleton | 67.2 | 22.4 | 10.3 |
| Muscle associated | 68.8 | 18.8 | 12.5 |
| Non-Muscle Associated | 66.7 | 23.8 | 9.5 |
| ECM | 60.0 | 30.0 | 10.0 |
| Metabolism | 54.8 | 21.4 | 9.5 |
| Carbohydrate | 50.0 | 16.7 | 33.3 |
| Non-Carbohydrate | 0.57 | 33.3 | 13.3 |
| Cell protection | 38.1 | 14.3 | 47.6 |
| Degradation | 91.7 | 00.0 | 7.3 |
| Ubiquit/Proteasome | 85.7 | 00.0 | 14.3 |
| Other | 100.0 | 00.0 | 00.0 |
| Cell cycle | 33.3 | 33.3 | 33.3 |
| G1/S | 43.6 | 28.6 | 28.6 |
| M | 11.1 | 55.6 | 33.3 |
| Other | 60.0 | 00.0 | 40.0 |
Number of highly regulated Xenopus proteins up regulated and down regulated at each time point after amputation and U/D ratios (bold)
| | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signaling | 39 | 44 | 58 | 38 | 52 | 34 | 60 | 35 | ||||
| Transport | 30 | 30 | 31 | 36 | 36 | 32 | 35 | 35 | ||||
| Transcription | 38 | 47 | 52 | 44 | 54 | 39 | 57 | 43 | ||||
| CA | 9 | 12 | 14 | 8 | 14 | 8 | 15 | 9 | ||||
| TFs | 18 | 14 | 17 | 22 | 18 | 18 | 20 | 18 | ||||
| RP | 11 | 21 | 21 | 14 | 22 | 13 | 22 | 16 | ||||
| Translation | 22 | 43 | 48 | 22 | 57 | 17 | 59 | 15 | ||||
| RPs | 16 | 30 | 33 | 16 | 40 | 12 | 42 | 10 | ||||
| TLFs | 6 | 13 | 15 | 6 | 17 | 5 | 17 | 5 | ||||
| Cytoskeleton | 34 | 43 | 45 | 50 | 48 | 49 | 60 | 43 | ||||
| MPs | 6 | 14 | 5 | 23 | 4 | 23 | 4 | 23 | ||||
| NMPs | 28 | 29 | 40 | 27 | 44 | 26 | 56 | 20 | ||||
| ECM | 24 | 12 | 30 | 7 | 28 | 8 | 28 | 11 | ||||
| Metabolism | 39 | 53 | 48 | 76 | 45 | 76 | 59 | 74 | ||||
| CM | 27 | 37 | 18 | 45 | 20 | 45 | 27 | 43 | ||||
| NCM | 12 | 16 | 30 | 31 | 25 | 31 | 32 | 31 | ||||
| Protection | 41 | 29 | 41 | 26 | 46 | 26 | 57 | 24 | ||||
| INF | 23 | 10 | 18 | 13 | 18 | 14 | 25 | 12 | ||||
| APO | 7 | 4 | 5 | 5 | 5 | 6 | 5 | 6 | ||||
| CHA | 11 | 15 | 18 | 8 | 23 | 6 | 27 | 6 | ||||
| Degradation | 28 | 28 | 30 | 26 | 32 | 25 | 39 | 24 | ||||
| PRO | 11 | 15 | 9 | 13 | 15 | 13 | 17 | 11 | ||||
| NPRO | 17 | 13 | 21 | 13 | 17 | 12 | 21 | 13 | ||||
| Cell cycle | 20 | 25 | 21 | 27 | 27 | 23 | 37 | 17 | ||||
| G1/S | 6 | 8 | 5 | 8 | 7 | 7 | 8 | 6 | ||||
| M | 4 | 8 | 8 | 10 | 8 | 9 | 13 | 5 | ||||
| Other | 10 | 9 | 8 | 9 | 12 | 7 | 16 | 6 | ||||
CA = chromatin associated; TFs = transcription factors; RP = RNA processing; RPs = ribosomal proteins; TLFs = translation factors; MPs = muscle proteins; NMPs = non-muscle proteins; CM = carbohydrate metabolism; NCM = non-carbohydrate metabolism; INF = inflammation; APO = apoptosis related; CHA = chaperones; PRO = proteasome associated; NPRO = non-proteasome associated.
Figure 3Validation of LC/MS/MS. Immunofluorescent antibody staining and mean densitometric sum for β1 integrin, vimentin, and dystroglycan, comparing control, 5 dpa and 12 dpa sections of regenerating froglet hindlimbs. A-D, β1 integrin; E-H, vimentin; I-L, dystroglycan. The 1, 5, 7 and 12 dpa fold changes for each of these proteins were: β1 integrin-1.05, 1.28, 2.18, 2.80; vimentin—1.07, 1.94, 2.30, 3.15; dystroglycan-1.20, -1.40, -1.49, -2.02. The immunofluorescence and densitometry data thus agree well with the LC/MS/MS proteomic data.
Number of axolotl proteins in each biological process category that are up regulated (U) or down regulated (D) on all dpa or 2 of 3 dpa, and U/D ratios
| Signaling | 43 | 23 | 20 | 1.3 |
| Transcription | 58 | 26 | 25 | 1.0 |
| Chromatin associated | 14 | 8 | 5 | 1.6 |
| Transcription factors | 22 | 11 | 7 | 1.6 |
| RNA processing | 22 | 7 | 13 | 0.5 |
| Translation | 20 | 14 | 3 | 4.7 |
| Ribosomal proteins | 13 | 9 | 2 | 4.5 |
| Translation factors | 7 | 5 | 1 | 5.0 |
| Cytoskeleton | 64 | 14 | 48 | 0.3 |
| Muscle proteins | 24 | 0 | 23 | 0.0 |
| Non-Muscle proteins | 46 | 14 | 25 | 0.6 |
| Extracellular matrix | 19 | 12 | 6 | 2.0 |
| Metabolism | 33 | 9 | 23 | 0.4 |
| Cell Protection | 35 | 16 | 16 | 1.0 |
| Inflammatory-Related | 8 | 6 | 2 | 3.0 |
| Apoptosis-Related | 13 | 5 | 8 | 0.6 |
| Chaperones | 14 | 5 | 6 | 0.8 |
| Degradation | 12 | 4 | 4 | 1.0 |
| Cell cycle | 13 | 7 | 4 | 1.8 |
| Total | 125 | 149 | 0.8 | |
Number of proteins common to blastema/fibroblastema formation in regenerating axolotl and Xenopus limbs
| Signaling | 10 (7.5) | 35 | 87 |
| Transport | 2 (2.7) | 6 | 68 |
| Transcription | 7 (4.5) | 50 | 98 |
| Translation | 15 (18.0) | 5 | 63 |
| Cytoskeleton | 25 (17.4) | 41 | 78 |
| Muscle | 10 (25.6) | 11 | 18 |
| Non-Muscle | 15 (14.3) | 30 | 60 |
| ECM | 4 (7.4) | 14 | 36 |
| Metabolism | 14 (9.0) | 19 | 121 |
| Cell protection | 10 (9.5) | 25 | 70 |
| Degradation | 5 (9.0) | 6 | 50 |
| Cell cycle | 0 (0.0) | 14 | 56 |
| Total | 92 (9.0) | 215 (21.0) | 727 (70.0) |
Numbers in parentheses indicate percent shared.
Proteins found in regenerating limbs of but not and proteins shared by the two species
| + APC | YWHAE (-/+) | |
| | + ARL1 | YWHAZ (-/+) |
| | GDI2 (NC/+) | |
| | - CLTCL1 | XG28K (+/+) |
| | - DIXDC1 | |
| | - ECTO | |
| | + EPHA7 | |
| | + EZR | |
| | + FHSB | |
| | + GNB2L1 | |
| | | |
| | | |
| | -IRF6.2 | |
| | | |
| | | |
| | | |
| | -LTBP4 | |
| | | |
| | | |
| | | |
| | - OR4D10 | |
| | -PPP2CB | |
| | -PTK6 | |
| | +RAB6B | |
| | -SYDE2 | |
| | -TBC1D17 | |
| | +TBCK | |
| | + TYK-2 | |
| | | |
| | - DNAH3 | |
| | + DYNC1LI2 | DYNLL1 (-/+) |
| | NC ANXA4 | ANXA1 (-/+) |
| | - ASPH | ANXA2 (-/+) |
| | ATP2A3 (-/-) | |
| + CACN1A | CASQ1 (+/-) | |
| | + CACNA2D3 | |
| | - CAMK2D | |
| | | |
| | - MYLC2PL | |
| | - SRL | |
| | | |
| 1. Chromatin associated | | |
| | + Histone 2A | H2AFY2 (+/+) |
| | | (H2AFX) (+/+) |
| | NC H2A.ZL1 | H1H4B (-/+) |
| | + H1H3A | |
| | - H1H3F | |
| | + H2H2AA4 | |
| | -H2BE | |
| | - H2BF | |
| | + HR | |
| | | |
| | + MTA1 | |
| | + NAP1L1-A | |
| 2. Transcription factors | | |
| | +AHCTF1 | FUBP1 (NC/+) |
| | - ATF1 | TRIM 29 (+/+) |
| | + CBTF122 | |
| | -E4F1 | |
| | + Lin 28 | |
| | | |
| | NEUROD2 | |
| | + NFATC4 | |
| | | |
| | +SND1 | |
| | + SOX6 | |
| | - TAF4 | |
| | + ZNF259 | |
| | + ZNF326 | |
| | - ZNF559 | |
| | + ZNF592 | |
| | + ZNF644 | |
| | | |
| | + Kruppel-like factor | |
| 3. RNA processing | | |
| | - CWC15 | SFRS1 (-/-) |
| | + DDX10 | |
| | - DDX46 | |
| | - FBL | |
| | - HNRNPF | |
| | - HNRNPH2 | |
| | - HNRNPH3 | |
| | + HNRNPL | |
| | + HNRNPU | |
| | + HNRNPAB | |
| | + KHSRP | |
| | - LSM4 | |
| | + MATR3 | |
| | - NHP2L1 | |
| | + RBM | |
| | - SART1 | |
| | - SFRS12 | |
| | + SFRS3 | |
| | - SNRPD3 | SNRPE (-/+) |
| | -SRRM1 | TARDBP (+/-) |
| | | |
| Ribosomal proteins: | + RPL31 | RPL12 (+/+) |
| | RPL15 (+/+) | |
| | | RPL22 (-/+) |
| | | RPL23 (-/+) |
| | | RPL30 (+/+) |
| | | RPL4 (+/-) |
| | | RPL7L1 (+/+) |
| | | RPLP0 (+/+) |
| | | RPS19 (+/-) |
| | | RPS28 (+/+) |
| | | RPS6 (+/-) |
| Translation factors: | + PABPC1 | EEF1A2 (+/+) |
| | - TARSL2 | EEF2 (+/+) |
| | + ETF1 | EIF4A1 (+/NC) |
| | | EIF4B (+/+) |
| | | |
| Muscle proteins: | - MYH3 | ACTA1 (-/-) |
| | - MYH4 | ACTN3 (-/-) |
| | - MYH7 | DES (-/+ & -) |
| | - MYH7B | MYBPC3 (-/+) |
| | - MYL2 | MYH13 (-/-) |
| | - MYL3 | MYL1 (-/-) |
| | - MYL5 | MYLPF (-/-) |
| | - NEB | TNNC2 (-/-) |
| | - OBSCN | |
| | TPM2 (-/-) | |
| | - TPM3 | |
| Non-Muscle proteins: | - ACTBL2 | ACTG1 (+/+) |
| | - ACTN1 | DESPLK (NC/+) |
| | - ACTN4 | DESPLK |
| | | Isoform II (-/+) |
| | + ACTR2-A | KRT12 (-/+) |
| | + EPPK1 | KRT19 (+/+) |
| | + FLNB | KRT5.5 (-/+) |
| | - GOLGA1 | PLS3 (-/+) |
| | NC Myo9A | EZR (+/+) |
| | TUBB2C (+/NC & +) | |
| | XAKB (-/- & +) | |
| | + TUBA | XAKC (-/+) |
| | + TUBA4B | CytoKer II (-/+) |
| | + TUBB4 | |
| | - DNAH3 | MVP (-/+) |
| | - MYH1 | DYNLL1 (-/+) |
| | -MYO1C | |
| | | |
| | - Myo5A | |
| | - PALM2 | |
| | - PDLIM1 | |
| | + CDH5 | |
| | - CNTNAP4 | |
| | | |
| | + ST3GAL5 | |
| | + SCARF2 | |
| | - KPNA2 | |
| | - MYOF | |
| | + PCLO | |
| | | |
| | | |
| | | |
| | + Col12A1 | |
| | + ColXIII1 | FGG ( |
| | + Col1A1 | FN1 (+/+) |
| | + Col1A1 pre-prot | MAT2 (+/+) |
| | - Col2A1 | |
| | - Col4A4 | |
| | + Col5A2 | |
| | - DCN | |
| | - EHD4 | |
| | + FBN1 | |
| | + MATN4 | |
| | - POSTN | |
| | | |
| | + TNN | |
| | | |
| | - ABCB10 | ATP5B (-/NC) |
| | - CS | COX5A (-/+) |
| | - ECHS1 | GLUD1 (-/+) |
| | - SLC25A13 | |
| | - ALDOC | |
| | - ENO3 | ALDOB (-/-) |
| | + PGAM3 | ENO11 (-/-) |
| | | PGM1 (-/-) |
| | | PGK2 (+/NC) |
| | | TPI1 (-/-) |
| | | |
| | + ACACA | AK1B (-/-) |
| | + ALDH6A1 | |
| | - CA3 | BHMT (-/-) |
| | -CPNE3 | |
| | | |
| | | |
| | - DSCR3 | |
| | - NPC2 | |
| | + PAPPA2 | |
| | - PNPLAS | |
| | - SGMS1 | |
| | + SULT1A4 | |
| | | |
| Inflammation: | - AOX1 | PRDX1 (+/+) |
| | | |
| | + GSTP1 | |
| | + OAS2 | |
| | +PXDN | |
| | + TLR6 | |
| Apoptosis: | + ABTB1 | PDCD6IP (-/+) |
| | - AK2 | |
| | - AKT1S1 | |
| | - BIRC6 | |
| | - FASTKD5 | |
| | + IL7R | |
| | + MAST3 | |
| | + MICB | |
| | + NEK11 | |
| | + PAIRBP1 | |
| | + TRAF1 | |
| | - VDAC1 | |
| Chaperones: | - HSP27 | CCT2 (+/+) |
| | + HSP90AB2P | FKBP10 (-/+) |
| | + HSPB3 | HSP90AA1 (-/+) |
| | - PCMT1 | HSP90B1 (+/+) |
| | + SSR1 | PDIA3 (-/+) |
| | + TOR1A | PDIA6 (+/+) |
| | + HSP90Kda | PPIA (+/+) |
| | isoform1 | P4HB (-/+) |
| | | |
| | EXOC7 | PSMB1 (+/-) |
| | HACE1 | |
| | MME | |
| | PSMD2 | |
| | PSMD7 | |
| | USP3 | |
| | | |
| | + CROCC | |
| | | |
| | - FUS | |
| | - LOH11CR2A | |
| | - MARK4 | |
| | -MMCM3 | |
| | + NDEL1 | |
| | + NMW1 | |
| | - PPP1CC | |
| | - RAN | |
| | + TTN | |
| | + ULA1 | |
| | - WDR36 | |
| - XMAP215 |
Bold indicates FC =/>2 on one or more dpa; + indicates up regulated; - indicates predominantly down regulated during blastema/fibroblastema formation. NC indicates no change. For the shared proteins, the first symbol(s) in parentheses indicate axolotl, and the second symbol(s) indicate Xenopus.